1
|
Expert A, Robba L, de Lagasnerie G, Kujas P. [Real-world study of the consumption between 2017 and 2020 of anti-cancer medications that inhibit cyclin- dependent kinases 4 and 6]. Bull Cancer 2023; 110:1272-1278. [PMID: 37802713 DOI: 10.1016/j.bulcan.2023.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 08/02/2023] [Accepted: 08/11/2023] [Indexed: 10/08/2023]
Abstract
The real-world study of data from the Système National des Données de Santé (French System of Health Data) in relation to therapeutic indications that give entitlement to having Assurance Maladie (Health-Insurance Fund) pay for, or reimburse the cost of, inhibitors of cyclin-dependent kinases 4 and 6 (iCDK4/6) shows that the target population defined by the Haute Autorité de santé (HAS-National Health Authority) has been significantly exceeded ; in addition, there is a gap with respect to reimbursable indications and therapeutic strategy. The HAS has set the upper limit of the eligible population at 5 320 new patients per year, but in 2019, Assurance Maladie reimbursed iCDK4/6-related costs for 10 894 patients, i.e. double the number. Therapeutic strategies are found that do not comply with the opinions of the commission de la transparence (transparency commission) in 30 % of cases, and that do not comply with reimbursable therapeutic indications in 22 % of cases. Patient profiles are not in line with reimbursable indications in terms of age (women aged under 50 and, a priori, non-menopausal) and sex (men) in 14 % of cases. Furthermore, treatment seems to be started at an advanced stage of the disease, based on the number of deaths observed after treatment is started: 13% of patients died in the year following the start of treatment, including 26 % in the first three months. There is a significant volume of treatment being started, but there is also a significant volume of stoppage. One third of patients for whom treatment was started in 2019 had their treatment stopped after less than one year, including half after less than three months.
Collapse
Affiliation(s)
- Aude Expert
- CNAM, 50, avenue du Professeur André-Lemierre, 75020 Paris, France.
| | - Laurence Robba
- CNAM, 50, avenue du Professeur André-Lemierre, 75020 Paris, France
| | | | - Paule Kujas
- CNAM, 50, avenue du Professeur André-Lemierre, 75020 Paris, France
| |
Collapse
|
2
|
Hamelin A, Amsler E, Mathelier-Fusade P, Pecquet C, Bayrou O, Barbaud A, Soria A. [Omalizumab for the treatment of chronic urticaria: Real-life findings]. Ann Dermatol Venereol 2019; 146:9-18. [PMID: 30638684 DOI: 10.1016/j.annder.2018.07.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 02/17/2018] [Accepted: 07/30/2018] [Indexed: 10/27/2022]
Abstract
OBJECTIVE Assessment of the efficacy and safety of omalizumab in chronic urticaria refractory to conventional treatment (H1-antihistamines at high dosage and montelukast) in real-life practice. PATIENTS AND METHODS A retrospective, descriptive, single-centre study was performed of the data for all patients presenting refractory chronic spontaneous urticaria or inducible urticaria and receiving omalizumab (300mg every four weeks) from November 2012 to June 2016. RESULTS In all, 23 patients were included. Omalizumab led to complete or significant remission in 19 patients (83%) with chronic urticaria, with remission in 9 patients (47%) occurring within 72hours of the first injection. One patient had a partial response and 3 (13%) showed no response. Only 2 patients (9%) in complete remission stopped their treatment at 1 and 3 years. 52% of patients presented non-serious adverse events, which in one case resulted in treatment withdrawal. CONCLUSION Omalizumab exhibited good real-life efficacy in a small series of chronic urticaria patients in France.
Collapse
Affiliation(s)
- A Hamelin
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
| | - E Amsler
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - P Mathelier-Fusade
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - C Pecquet
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - O Bayrou
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - A Barbaud
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Faculté de médecine, Sorbonne université, 75006 Paris, France
| | - A Soria
- Service de dermatologie et allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Inserm U1135, Cimi-Paris, centre d'immunologie et de maladies infectieuses, 75013 Paris, France
| |
Collapse
|
3
|
Launois R, Trouiller JB, Cabout E. [How to measure real-world effectiveness?]. Ann Pharm Fr 2018; 76:421-35. [PMID: 30103940 DOI: 10.1016/j.pharma.2018.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 07/03/2018] [Accepted: 07/06/2018] [Indexed: 01/17/2023]
Abstract
The new use of medico-administrative databases is a major change in the medical assessment field. Given the limits of the randomized clinical trials when it comes to accurately represent the heterogeneity and complexity of medical care in a real-world context, an increasing demand of observational studies comes from healthcare systems as decision tools. The lack of intervention generates real-world data and assesses both the care and the outcomes of patients in routine practice. Despite this external validity, the bias and confounding factors are a challenge to the internal validity of observational studies. An appropriate study design and statistical methods are necessary to neutralize them and consider a causal relationship between a treatment and a clinical outcome.
Collapse
|